Skip to main content
main-content

Connective tissue diseases

Systemic lupus erythematosus

09-07-2019 | Systemic lupus erythematosus | Highlight | News

Pregnancy outcomes improving for women with SLE

In the past two decades pregnancy outcomes, including in-hospital maternal mortality, have improved among women with systemic lupus erythematosus, but further improvements are needed to reduce risks further, US research shows.

Pregnancy outcomes improving for women with SLE

In the past two decades pregnancy outcomes, including in-hospital maternal mortality, have improved among women with systemic lupus erythematosus, but further improvements are needed to reduce risks further, US research shows.

28-06-2019 | Systemic lupus erythematosus | News

Glucocorticoid withdrawal an achievable goal in patients with SLE

Glucocorticoid tapering and complete withdrawal can be achieved in patients with systemic lupus erythematosus and may be particularly successful in those with long-term remission or low disease activity, Italian researchers report.

20-06-2019 | Systemic lupus erythematosus | Highlight | Article

Systemic lupus erythematosus: Novel therapies and targeted treatments

Andrea Fava and George Stojan review new strategies and agents for the treatment of systemic lupus erythematosus that have most recently showed promise in clinical trials.

Systemic lupus erythematosus: Novel therapies and targeted treatments

Andrea Fava and George Stojan review new strategies and agents for the treatment of systemic lupus erythematosus that have most recently showed promise in clinical trials.

28-05-2019 | Systemic lupus erythematosus | News

Predictors of rituximab response identified in patients with SLE

A real-world study of patients with systemic lupus erythematosus suggests that those with more active disease and minimal previous immunosuppressive treatment are most likely to benefit from single-course treatment with rituximab.

14-05-2019 | Systemic lupus erythematosus | News

Individualized tool aids treatment decision-making for women with lupus nephritis

SMILE, an individualized and culturally tailored patient decision aid, has been shown to reduce decisional conflict regarding choice of immunosuppressive treatment in a randomized trial involving a diverse group of women with lupus nephritis.

07-05-2019 | Systemic lupus erythematosus | Podcast | Article

A closer look at the EULAR guidelines for managing lupus

Antonis Fanouriakis, lead author of the updated EULAR guidelines for the management of lupus, talks to medwireNews about what’s new in these guidelines and how they will influence clinical practice.

07-05-2019 | Systemic lupus erythematosus | Article

Editorial board comment

Comment on: Belimumab approved for pediatric lupus in the USA

02-05-2019 | Systemic lupus erythematosus | News

Multifactorial nature of cognitive dysfunction highlighted in SLE

Poor attenuation of the default mode network regions of the brain may contribute to cognitive impairments in patients with systemic lupus erythematosus, say UK researchers.

09-04-2019 | Systemic lupus erythematosus | News

Updated EULAR guidelines for lupus management issued

EULAR has published up-to-date recommendations for the management of systemic lupus erythematosus based on emerging evidence and expert opinion.

27-02-2019 | Systemic lupus erythematosus | News

Add-on belimumab efficacy maintained for up to 13 years in SLE patients

Individuals with systemic lupus erythematosus who respond to belimumab plus standard of care therapy can hope to experience long-term disease control, suggests a trial in which participants received treatment for up to 13 years.

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

02-01-2019 | Systemic lupus erythematosus | Highlight | News

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

17-12-2018 | Systemic lupus erythematosus | News

Lupus tied to increased cancer risk

Findings from a meta-analysis indicate that systemic lupus erythematosus is associated with an increased risk for 16 types of cancer.

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

11-12-2018 | Systemic lupus erythematosus | Article

New therapeutic strategies in systemic lupus erythematosus management

Gatto M et al. Nat Rev Rheum 2018. doi: 10.1038/s41584-018-0133-2

Image Credits